China’s Drug-Buying Growth Attracts Japanese Makers
This article was originally published in PharmAsia News
Executive Summary
China's double-digit growth in pharmaceutical purchases has sparked an interest in Japanese drug makers in expanding their own markets in the country. The Chinese market is soon to surpass Japan to become the world's second-largest, behind only the United States. Astellas Pharma also has scheduled release of one of its drugs for later this year, Eisai is adding representatives and Dainippon Sumitomo Pharma now has a Chinese subsidiary. The Japanese makers see China as a replacement for dwindling markets in the United States and the European Union as the Chinese become more affluent. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.